Currently, three of the drugs approved for the treatment of AD are AChE inhibitors (donepezil, galantamine, and rivastigmine), one is an uncompetitive antagonist of N-Methyl-D-aspartate receptors (NMDA) (memantine), and the Food and Drugs Administration approved two monoclonal antibodies against Aβ (aducanumab and lecanemab) [20,21,22,23]. The gene discussed is ACHE; the disease is Alzheimer disease.